目的探讨人源抗甲型肝炎病毒全抗体分子在杆状病毒中的表达。
Objective To develop human recombinant neutralizing IgG monoclonal antibodies to hepatitis A virus (HAV) by baculovirus expression system.
本发明提供了高效表达治疗肿瘤并含有人恒定区全抗体的重组病毒及其用途。
The present invention provides recombinant virus with high efficiency expression to treat tumor and containing all antibody of human constant region.
全血检查，包括血小板计数、纤维蛋白原水平、部分凝血活酶时间、ABO血型和抗体监测。
CBC with platelet count, fibrinogen level, partial thromboplastin time, and ABO blood typing and antibody screen are obtained.
抗SSA和抗SSB抗体、ESR、血清蛋白电泳检测分别采用免疫双扩散法、魏氏法、全自凝胶法。
Double diffusion method, Westergren and automatic gel method detected ant-SSA and ant-SSB antibody, ESR and serum protein electrophoresis respectively.
将经CD 34单克隆抗体鉴定后的CD 34 +细胞移植入脊髓全横断大鼠模型脊髓横断处尾侧。
The CD34 + cells after identified by anti-CD34 monoclonal antibodies were transferred into the caudal of transaction of rat model.
方法：新鲜抗凝全血，经CD 14单克隆抗体标记，采用流式细胞仪区分单核细胞及其表面CD 14的表达。
Methods: Fresh anticoagulant blood was labelled by CD14 monoclonal antibody, then monocytes were identified and the expressions of CD14 were tested by flow cytometry.
本研究通过LMG全抗原的合成和抗体的制备，初步建立了L MG的ELISA测定方法。
This research synthesized the antigen and developed the antibodies, and established the ELISA method for detecting LMG.
但是全病毒不同蛋白抗原引起的抗体水平有所差别，S2蛋白最强。
However, the levels of antibodies induced by different antigenic proteins of SARS-CoV were different, the best was by S2 protein.
【译】甲型流感病毒的中和抗体h7n9的全病毒灭活在小鼠和非人灵长类动物的诱导。
Induction of neutralizing antibodies to influenza a virus H7N9 by inactivated whole virus in mice and nonhuman primates.
无法治疗到全阴，只能用药物让其产生抗体。
Cannot treat whole nether world, can let its produce antibody with medicaments only.
方法以不同剂量霍乱疫苗免疫小鼠，用间接elisa方法检测小鼠全血的抗菌、抗毒抗体滴度，小鼠毒菌攻击法计算保护率。
Methods The mice were immunized by different doses of cholera vaccine. Titer of antiserum against cholera strain and toxin were tested by indirect enzyme-linked immunosorbent assay (ELISA).
全菌灭活疫苗浸泡免疫、注射免疫和微囊化疫苗口服免疫的抗体滴度（凝集抗体效价）平均分别为1：19、1：190、1：62；
The average antibody titers(agglutination titer)of the Whole-cell vaccine immunization, injection immunization and microencapsulated vaccine oral immunization were respectively 1:19,1:190,1:62;
全菌灭活疫苗浸泡免疫、注射免疫和微囊化疫苗口服免疫的抗体滴度（凝集抗体效价）平均分别为1：19、1：190、1：62；
The average antibody titers(agglutination titer)of the Whole-cell vaccine immunization, injection immunization and microencapsulated vaccine oral immunization were respectively 1:19,1:190,1:62;
应用推荐